Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 10c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.53), $0.10 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $34.17 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Take-Two Interactive (TTWO) Reiterated at Buy by StoneX Ahead of November GTA VI Launch
• SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks